Evidence map›Paper›PMID 32206963›Full record

ReviewApplied psychophysiology and biofeedback2020

Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines.

Martijn Arns, C Richard Clark, Mark Trullinger, Roger deBeus, Martha Mack, Michelle Aniftos

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Applied psychophysiology and biofeedback, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 7 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 7 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Closed-Loop Neurofeedback of α Synchrony during Goal-Directed Attention.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Martijn ArnsResearch Institute Brainclinics, Brainclinics Foundation, Bijleveldsingel 34, 6524 AD, Nijmegen, The Netherlands. martijn@brainclinics.com.
C Richard ClarkCollege of Education, Psychology and Social Work, Flinders University of South Australia, Adelaide, SA, Australia.
Mark TrullingerThe Chicago School of Professional Psychology, Washington, D.C., USA.
Roger deBeusDepartment Psychology, University of North Carolina at Asheville, Asheville, NC, USA.
Martha MackApplied Neuroscience Society of Australasia (ANSA), Brisbane, Australia.
Michelle AniftosApplied Neuroscience Society of Australasia (ANSA), Brisbane, Australia.
Brainclinics · NLFlinders University · AUInternational Society of Nephrology · BEMelbourne Health · AUTechnoServe · USToowoomba Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimulant medication and behaviour therapy are the most often applied and accepted treatments for Attention-Deficit/Hyperactivity-Disorder (ADHD). Here we explore where the non-pharmacological clinical intervention known as neurofeedback (NFB), fits on the continuum of empirically supported treatments, using standard protocols. In this quantitative review we utilized an updated and stricter version of the APA guidelines for rating 'well-established' treatments and focused on efficacy and effectiveness using effect-sizes (ES) and remission, with a focus on long-term effects. Efficacy and effectiveness are compared to medication and behaviour therapy using benchmark studies. Only recent systematic reviews and meta-analyses as well as multi-centre randomized controlled trials (RCT's) will be included. Two meta-analyses confirmed significant efficacy of standard neurofeedback protocols for parent and teacher rated symptoms with a medium effect size, and sustained effects after 6-12 months. Four multicenter RCT's demonstrated significant superiority to semi-active control groups, with medium-large effect sizes end of treatment or follow-up and remission rates of 32-47%. Effectiveness in open-label studies was confirmed, no signs of publication bias were found and no significant neurofeedback-specific side effects have been reported. Standard neurofeedback protocols in the treatment of ADHD can be concluded to be a well-established treatment with medium to large effect sizes and 32-47% remission rates and sustained effects as assessed after 6-12 months.

Indexed as

NeurofeedbackOutcome Assessment, Health CarePractice Guidelines as TopicAttention Deficit Disorder with HyperactivityChildHumansADHDEffect sizeNeurofeedbackRemissionReview

Identifiers

PMID32206963
PMCPMC7250955
OpenAlexW3012868413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.